AstraZeneca wins FDA breakthrough status for key cancer drug
LONDON, Feb 17 (Reuters) - The U.S. Food and Drug Administration has granted breakthrough therapy designation to AstraZeneca's biggest new drug hope durvalumab as a treatment in bladder cancer, the drugmaker said on Wednesday.
No comments:
Post a Comment